Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDC25A | P30304 | 6/20 | 0.69 |
| ▸ | CDC25B | P30305 | 4/20 | 0.69 |
| ▸ | DHCR24 | Q15392 | 2/20 | 0.46 |
| ▸ | GPBAR1 | Q8TDU6 | 7/20 | 0.43 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.43 |
| ▸ | NR1H4 | Q96RI1 | 3/20 | 0.42 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.39 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.39 |
| ▸ | EFNA1 | P20827 | 1/20 | 0.39 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.39 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.39 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.39 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.39 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.39 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.39 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10041425 | 1.00 | CDC25A (0.69) | CDC25ACDC25BDHCR24GPBAR1SRD5A2 | |
| SCHEMBL14107818 | 1.00 | CDC25A (0.69) | CDC25ACDC25BDHCR24GPBAR1SRD5A2 | |
| SCHEMBL6695435 | 1.00 | CDC25A (0.69) | CDC25ACDC25BDHCR24GPBAR1SRD5A2 | |
| SCHEMBL13392550 | 1.00 | CDC25A (0.69) | CDC25ACDC25BDHCR24GPBAR1SRD5A2 | |
| SCHEMBL10125283 | 1.00 | CDC25A (0.69) | CDC25ACDC25BDHCR24GPBAR1SRD5A2 | |
| SCHEMBL2609728 | 1.00 | CDC25A (0.69) | CDC25ACDC25BDHCR24GPBAR1SRD5A2 | |
| SCHEMBL10125341 | 1.00 | CDC25A (0.69) | CDC25ACDC25BDHCR24GPBAR1SRD5A2 | |
| SCHEMBL12288852 | 1.00 | CDC25A (0.69) | CDC25ACDC25BDHCR24GPBAR1SRD5A2 | |
| SCHEMBL15494063 | 1.00 | CDC25A (0.69) | CDC25ACDC25BDHCR24GPBAR1SRD5A2 | |
| SCHEMBL2678324 | 1.00 | CDC25A (0.69) | CDC25ACDC25BDHCR24GPBAR1SRD5A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-8301811-A | — | — | None | — | — | JP | disclosed |
| EP-2419403-B1 | VITAMIN D RECEPTOR AGONISTS AND USES THEREOF | VIDASYM INC (US) | 2016-09-07 | — | — | EP | disclosed |
| US-20120115824-A1 | Vitamin D Receptor Agonists and Uses Thereof | VIDASYM, LLC (US) | 2012-05-10 | — | — | US | disclosed |
| US-20120115824-A1 | Vitamin D Receptor Agonists and Uses Thereof | VIDASYM, LLC (US) | 2012-05-10 | — | — | US | disclosed |
| WO-2010120698-A1 | VITAMIN D RECEPTOR AGONISTS AND USES THEREOF | VIDASYM, LLC (US) | 2010-10-21 | — | — | WO | disclosed |
| US-20100093675-A1 | NOVEL METHOD | BIOXELL S.P.A. (IT) | 2010-04-15 | — | — | US | disclosed |
| US-20100069339-A1 | NOVEL METHOD OF TREATMENT OF MALE SUB-FERTILITY | BIOXELL S.P.A. (IT) | 2010-03-18 | — | — | US | disclosed |
| US-20100009949-A1 | NOVEL METHOD | BIOXELL S.P.A. (IT) | 2010-01-14 | — | — | US | disclosed |
| CN-101541330-A | Use of vitamin D compounds for preventing adhesions | BIOXELL SPA (IT) | 2009-09-23 | — | — | CN | disclosed |
| CN-101522199-A | Novel method of treatment of male sub-fertility | BIOXELL SPA (IT) | 2009-09-02 | — | — | CN | disclosed |
| CN-101287705-A | Synthesis of 1 alpha-fluoro-25-hydroxy-16-23E-diene-26, 27-bishomo-20-epi-cholecalciferol | BIOXELL SPA (IT) | 2008-10-15 | — | — | CN | disclosed |
| WO-2008091686-A2 | SYNTHESIS OF 1α-FLUORO-25-HYDROXY-16-23E-DIENE-26,27-BISHOMO-20-EPI-CHOLECALCIFEROL | BIOXELL S.P.A. (IT) | 2008-07-31 | — | — | WO | disclosed |
| EP-1924268-A2 | SYNTHESIS OF 1ALPHA-FLUORO-25-HYDROXY-16-23E-DIENE-26,27-BISHOMO-20-EPI-CHOLECALCIFEROL | Bioxell S.p.a. (IT) | 2008-05-28 | — | — | EP | disclosed |
| WO-2008043857-A2 | NOVEL METHOD OF TREATMENT OF MALE SUB-FERTILITY | BIOXELL SPA (IT) | 2008-04-17 | — | — | WO | disclosed |
| WO-2008034908-A2 | USE OF VITAMIN D COMPOUNDS FOR THE PREVENTION OF ADHESIONS | BIOXELL SPA (IT) | 2008-03-27 | — | — | WO | disclosed |
| WO-2007110109-A1 | NOVEL METHOD | BIOXELL SPA (IT) | 2007-10-04 | — | — | WO | disclosed |
| WO-2007022433-A2 | SYNTHESIS OF 1α-FLUORO-25-HYDROXY-16-23E-DIENE-26,27-BISHOMO-20-EPI-CHOLECALCIFEROL | BIOXELL S.P.A. (IT) | 2007-02-22 | — | — | WO | disclosed |
| US-5939408-A | COMPOUNDS FOR TREATMENT OF SKIN DISORDERS, ANTITUMOR AGENTS AND SEBACEOUS GLAND DISEASE | HOFFMAN-LA ROCHE INC. (US) | 1999-08-17 | — | — | US | disclosed |
| JP-H08301811-A | HYDROINDAN-4-OL DERIVATIVE AND ITS PRODUCTION | KURARAY CO LTD | 1996-11-19 | — | — | JP | disclosed |
| EP-0326875-A1 | Didehydro-vitamin D3 derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 1989-08-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069339-A1 | NOVEL METHOD OF TREATMENT OF MALE SUB-FERTILITY | CYP27B1, CYP2R1, SHBG | CDC25A 3455/4885CDC25B 3024/4885DHCR24 86/4885 |
| US-20120115824-A1 | Vitamin D Receptor Agonists and Uses Thereof | VDR, CYP2R1, CYP24A1 | CDC25A 2783/4885CDC25B 3344/4885DHCR24 667/4885 |
| US-20100009949-A1 | NOVEL METHOD | CYP24A1, CYP2R1, CYP27B1 | CDC25A 2464/4885CDC25B 2125/4885DHCR24 33/4885 |
| US-20100093675-A1 | NOVEL METHOD | GC, VDR, CYP24A1 | CDC25A 1883/4885CDC25B 1661/4885DHCR24 314/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.